Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases

Dr. Howard Berman, Ph.D, CEO of Coya Therapeutics Inc COYA, were guests on Benzinga’s All Access.

Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. The company is currently developing multi-modality Treg therapies for neurodegenerative, autoimmune and metabolic diseases.

Coya has secured key financing that is funding its research and development to enhance the body’s T cells.

Watch the full interview here:


Featured photo by Hal Gatewood on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechGeneralCoya Therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!